Novel device-delivery company emerges from stealth mode after receiving $15 million Series B from GSK's VC arm

May 17, 2011 | Analyst Insight

SpringLeaf Therapeutics, a Boston-based device-delivery company, emerged from stealth mode last week with the announcement of a $15 million Series B financing round led by the corporate venture capital arm of...